PMID- 22891759
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20181202
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 18
IP  - 23-24
DP  - 2012 Dec
TI  - Amniotic fluid-derived stem cells as a cell source for bone tissue engineering.
PG  - 2518-27
LID - 10.1089/ten.tea.2011.0672 [doi]
AB  - In tissue engineering, stem cells have become an ideal cell source that can 
      differentiate into most human cell types. Among the stem cells, bone 
      marrow-derived stem cells (BMSCs) have been widely studied, and there is strong 
      evidence that these cells can be differentiated into cells of the osteogenic 
      lineage. Thus, BMSCs have become the gold standard for studies of tissue 
      engineering in orthopedics. However, novel stem cell sources, such as amniotic 
      fluid-derived stem cells (AFSCs) have been identified, and these have important 
      and unique features that may lead to novel and successful applications toward the 
      regeneration of bone tissue. This study was designed to originally compare the 
      osteogenic potential of both BMSCs and AFSCs under distinct culture environments 
      to determine whether the osteogenic differentiation process of both types of stem 
      cells is related to the origin of the cells. Osteogenic differentiation was 
      carried out in both two and three dimensions using a tissue culture plate and by 
      means of seeding the cells onto microfibrous starch and poly(varepsilon-caprolactone) 
      scaffolds (a blend of starch and polycaprolactone), respectively. BMSCs and AFSCs 
      were successfully differentiated into the osteogenic cell type, as cells derived 
      from them produced a mineralized extracellular matrix. Nevertheless, the two 
      types of cells presented different expression patterns of bone-related markers as 
      well as different timing of differentiation, indicating that both cell origin and 
      the culture environment have a significant impact on the differentiation into the 
      osteogenic phenotype in AFSCs and BMSCs.
FAU - Rodrigues, Marcia T
AU  - Rodrigues MT
AD  - Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, 
      Winston-Salem, North Carolina, USA.
FAU - Lee, Sang Jin
AU  - Lee SJ
FAU - Gomes, Manuela E
AU  - Gomes ME
FAU - Reis, Rui L
AU  - Reis RL
FAU - Atala, Anthony
AU  - Atala A
FAU - Yoo, James J
AU  - Yoo JJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120814
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Core Binding Factor Alpha 1 Subunit)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Polyesters)
RN  - 0 (RUNX2 protein, human)
RN  - 24980-41-4 (polycaprolactone)
RN  - 9005-25-8 (Starch)
RN  - EC 3.1.3.1 (ALPL protein, human)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Alkaline Phosphatase/biosynthesis/genetics
MH  - Amniotic Fluid/*cytology
MH  - Calcification, Physiologic
MH  - Calcium/metabolism
MH  - Cell Culture Techniques/instrumentation
MH  - Cell Separation
MH  - Core Binding Factor Alpha 1 Subunit/biosynthesis/genetics
MH  - Extracellular Matrix/metabolism
MH  - Extracellular Matrix Proteins/biosynthesis/genetics
MH  - Gene Expression Regulation
MH  - Humans
MH  - Mesenchymal Stem Cells/cytology/metabolism
MH  - Organ Specificity
MH  - *Osteogenesis
MH  - Polyesters
MH  - Starch
MH  - Stem Cells/*cytology/metabolism
MH  - Time Factors
MH  - Tissue Engineering/instrumentation/*methods
MH  - Tissue Scaffolds
EDAT- 2012/08/16 06:00
MHDA- 2013/05/03 06:00
CRDT- 2012/08/16 06:00
PHST- 2012/08/16 06:00 [entrez]
PHST- 2012/08/16 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
AID - 10.1089/ten.tea.2011.0672 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2012 Dec;18(23-24):2518-27. doi: 10.1089/ten.tea.2011.0672. 
      Epub 2012 Aug 14.